Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes (PRIME)

1 novembre 2026 aggiornato da: Maja Guberina, University Hospital, Essen

High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes; PRIME: P: Precision R: Radiosurgery I: Intervention M: Minimal Invasive Surgical Approach E: EYESIGHT

High-precision radiosurgery followed by minimally invasive surgical approach in patients with high-prominence uveal melanomas: modern radiation techniques and outcomes. Evaluation of outcome regarding multiparametric parameters and co-factors

Panoramica dello studio

Descrizione dettagliata

The aim here is to prospectively evaluate modern technical standards. The aim of this study is to assess the influence of the updated basic diagnostics and high-resolution diagnostics for radiation planning and the new technical therapy standards (therapy options in application: volume modulated rapid arc technique (VMAT) / online arc technique (VMAT) / online onboard image-guidance (IGRT), by means of the newly established Clinic for Radiation Therapy 2019-2021) depending on known prognostic parameters for quality assurance of the long-term outcome (overall survival, local tumor control). This will lay the basis for standardizing treatment parameters as far as possible, but also to introduce improvements in the treatment of future patients.

Scientific background (state of research (with literature references) and

Derivation of the research question (rationale)):

The eye can be affected by several neoplastic processes, which can lead either primarily or secondary to systemic metastasis. The most common primary tumors of the eye include conjunctival melanoma and uveal melanoma. Metastases from systemic malignant diseases, particularly of the breast and lungs, can also affect the eye.

A combination of ophthalmologic examination, MRI and additional tests and cytologic/histopathologic evaluation leads to an accurate diagnosis.

Depending on the tumor manifestation, treatment consists of a multimodal concept. In the case of uveal melanomas and the aim of preserving the globe and and visual acuity preservation, radiotherapy is one of the most important treatment modalities that can be applied.

In the last 20 years, radiotherapy has developed rapidly away from two-dimensional modulated, three-dimensional techniques. But here too the high level of technical diversity in radiotherapy and ever newer technical innovations, there is a broad spectrum of radiotherapy. Standard therapy can be performed using modern devices, the high-precision stereotactic linear accelerators (irradiation devices), can be safely further optimized. This is to be tested in the Department of Radiotherapy.

Tipo di studio

Osservativo

Iscrizione (Stimato)

250

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Essen, Germania
        • Reclutamento
        • University Hospital Essen
        • Contatto:
      • Essen, Germania, 45147
        • Reclutamento
        • Maja Guberina
        • Contatto:
    • Germany / NRW
      • Essen, Germany / NRW, Germania, 45147
        • Reclutamento
        • Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West
        • Contatto:
        • Contatto:
          • Ina Grübel
        • Investigatore principale:
          • Maja Guberina, PD Dr. med. (MD)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Inclusion Criteria:

- Resectability, high-prominent and high risk uveal melanoma

Exclusion Criteria:

  • EOE
  • lux defect (If a medical report notes a "lux defect" alongside this, it refers to a deficit in light perception (from the Latin lux for light). It means the eye's ability to sense light, darkness, or light direction is impaired)

Descrizione

Inclusion Criteria:

  • Functional Resectability,
  • Technical Resectability
  • high-prominent uveal melanoma

Exclusion Criteria:

  • EOE
  • At least in part remaining eye function that can be saved

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Local control
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Local control

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual acuity:
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual function assessed separately for each eye. Visual acuity:

decimal scale,range 2,0 - 0,01: decimal acuity scale

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Quality of Life, ophthalmic cancer-specific quality of life
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Quality of Life, ophthalmic cancer-specific quality of life

1) EORTC QLQ-OPT30 (ophthalmic cancer-specific quality of life): Scores range from 0-100; higher scores indicate greater visual impairment, ocular symptoms, and functional difficulties.

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Progression Free Survival
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Progression Free Survival

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Overall Survival
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Overall Survival

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual acuity:
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual function assessed separately for each eye. Visual acuity:

decimal scale,range 2,0 - 0,01: decimal acuity scale; furthermore, 1.Count-fingers, 2.hand-motion and 3.light-perception categories are recorded separately when acuity cannot be quantified: for each item: value yes / no

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual field
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual field: Automated perimetry, Visual Field Index (VFI, %): 0 % - 100%,

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Quality of Life general quality of life
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

EORTC QLQ-C30 (general quality of life): Scores range from 0-100; A) higher scores indicate better functioning/global quality of life B) symptom scores: indicate greater symptom burden on symptom scales.

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Retinal Nerve Fiber Layer
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Optical coherence tomography (OCT): Peripapillary retinal nerve fiber layer (RNFL) thickness, measured in µm and classified in percentiles (regarding normal values)

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Cornea
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

corneal outcome: thickness measured in µm

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Cornea
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Corneal outcome modified Stocker's classification:

category 0 No damage no injury category 1 corneal guttae without epithelial or stromal edema. category 2 corneal guttae with epithelial or stromal edema. category 3 corneal edema associated with scar formation. category 4 corneal opacification with neovascularization, modified Stocker's classification

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Corneal overall outcome classification
Lasso di tempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

category 0 No corneal-ulcus category 1 Irregular punctate epithelial defects category 2 Non-healing epithelial defects / persistent epithelial defect (PED) category 3 Ulcer perforation

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 settembre 2019

Completamento primario (Stimato)

30 giugno 2027

Completamento dello studio (Stimato)

30 giugno 2032

Date di iscrizione allo studio

Primo inviato

18 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

1 novembre 2026

Primo Inserito (Effettivo)

3 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Descrizione del piano IPD

dependent on the project

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi